Evidence map›Paper›PMID 33907743›Full record

ArticlebioRxiv : the preprint server for biology2021

Sentinel cells enable genetic detection of SARS-CoV-2 Spike protein.

Zara Y Weinberg, Claire E Hilburger, Matthew Kim, Longxing Cao, Mir Khalid, Sarah Elmes, Devan Diwanji, Evelyn Hernandez, Jocelyne Lopez, Kaitlin Schaefer and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Zara Y WeinbergDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA.
Claire E HilburgerThe UC Berkeley-UCSF Graduate Program in Bioengineering, UC Berkeley, Berkeley, CA.
Matthew KimDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA.
Longxing CaoDepartment of Biochemistry, University of Washington, Seattle, WA.
Mir KhalidGladstone Institute of Virology, San Francisco, CA.
Sarah ElmesLaboratory for Cell Analysis, University of California, San Francisco, CA.
Devan DiwanjiCardiovascular Research Institute, University of California San Francisco, CA.
Evelyn HernandezDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA.
Jocelyne LopezHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.
Kaitlin SchaeferDepartment of Pharmacology, University of California, San Francisco, CA.
Amber M SmithDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA.
Fengbo ZhouDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA.
QCRG Structural Biology Consortium
G Renuka KumarGladstone Institute of Virology, San Francisco, CA.
Melanie OttGladstone Institute of Virology, San Francisco, CA.
David BakerDepartment of Biochemistry, University of Washington, Seattle, WA.
Hana El-SamadDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA.

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007618 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ANDERSON, MARK S · 1985 to 2020
$29.6M
UCSF IRACDA Scholars ProgramK12GM081266 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Raymond M. Esquerra, HOLLY A. INGRAHAM · 2007 to 2026
$19.4M
Integrative Program in Complex Biological System (ipCBS)T32EB009383 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARSHALL, WALLACE, WEINER, ORION D · 2009 to 2022
$3.2M
NCI NIH HHS P30 CA082103NIBIB NIH HHS T32 EB009383NIGMS NIH HHS K12 GM081266NIGMS NIH HHS T32 GM007618
6 · The paper itself

Abstract

The COVID-19 pandemic has demonstrated the need for exploring different diagnostic and therapeutic modalities to tackle future viral threats. In this vein, we propose the idea of sentinel cells, cellular biosensors capable of detecting viral antigens and responding to them with customizable responses. Using SARS-CoV-2 as a test case, we developed a live cell sensor (SARSNotch) using a de novo-designed protein binder against the SARS-CoV-2 Spike protein. SARSNotch is capable of driving custom genetically-encoded payloads in immortalized cell lines or in primary T lymphocytes in response to purified SARS-CoV-2 Spike or in the presence of Spike-expressing cells. Furthermore, SARSNotch is functional in a cellular system used in directed evolution platforms for development of better binders or therapeutics. In keeping with the rapid dissemination of scientific knowledge that has characterized the incredible scientific response to the ongoing pandemic, we extend an open invitation for others to make use of and improve SARSNotch sentinel cells in the hopes of unlocking the potential of the next generation of smart antiviral therapeutics.

Identifiers

PMID33907743
PMCPMC8077567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.